Quotient Ltd (QTNT): Stephen Unger , Chief Financial Officer of Quotient Ltd sold 8,516 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $10.60 per share for a total value of $89,347.94 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 11, 2016, Zubeen Shroff (director 10% owner) purchased 222,222 shares at $9.00 per share price.On Jun 4, 2015, Sarah A Oconnor (director) purchased 10,000 shares at $15.50 per share price.Also, On Mar 16, 2015, Stephen Unger (Cheif Financial Officer) purchased 3,000 shares at $15.00 per share price.On Mar 10, 2015, D J Paul E Cowan (director officer 10% owner ) sold 75,000 shares at $16.80 per share price.
Shares of Quotient Ltd (QTNT) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.34 points or -3.32% at $9.9 with 38,185 shares getting traded. Post opening the session at $10.4999, the shares hit an intraday low of $9.69 and an intraday high of $10.4999 and the price vacillated in this range throughout the day. The company has a market cap of $252 M and the number of outstanding shares has been calculated to be 2,54,08,950 shares. The 52-week high of Quotient Ltd is $19.9499 and the 52-week low is $6.5.
Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood which includes antigen typing and antibody identification. Serological disease screening involves the screening of donor blood for unwanted pathogens. The Company is engaged in the development manufacturing and commercialization of conventional reagent products for blood grouping. The Company also undertakes product development projects for its original equipment manufacturer (OEM) customers. The Company develops manufactures and commercializes the products including Antisera products Reagent Red Blood Cells Whole Blood Controls and Ancillary products. The Company is developing MosaiQ to characterize donor and patient blood and serologically screen donor blood for specific viruses.